Page 2328 - Williams Hematology ( PDFDrive )

2302 Part XII: Hemostasis and Thrombosis <CN>: Atherothrombosis: Disease Initiation, Progression, and Treatment PB

235. Lewis HD Jr, Davis JW, Archibald DG, et al: Protective effects of aspirin against acute 256. Norgren L, Hiatt WR, Dormandy JA, et al: Inter-Society Consensus for the Manage-
myocardial infarction and death in men with unstable angina. Results of a Veterans ment of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 Suppl
Administration Cooperative Study. N Engl J Med 309:396–403, 1983. 1:S1–S75, 2007.
236. Cairns JA, Gent M, Singer J, et al: Aspirin, sulfinpyrazone, or both in unstable angina. 257. Goyen M, Edelman M, Perreault P, et al: MR angiography of aortoiliac occlusive dis-
Results of a Canadian multicenter trial. N Engl J Med 313:1369–1375, 1985. ease: A phase III study of the safety and effectiveness of the blood-pool contrast agent
237. Boersma E, Harrington RA, Moliterno DJ, et al: Platelet glycoprotein IIb/IIIa inhibitors MS-325. Radiology 236:825–833, 2005.
in acute coronary syndromes. Lancet 360:342–343, 2002. 258. Mohler ER 3rd. Therapy insight: Peripheral arterial disease and diabetes—From patho-
238. Gaglia MA Jr, Clavijo L: Cardiovascular pharmacology core reviews: Aspirin. J Cardio- genesis to treatment guidelines. Nat Clin Pract Cardiovasc Med 4:151–162, 2007.
vasc Pharmacol Ther 18:505–513, 2013. 259. Mohler ER, Jaff MR: Peripheral Arterial Disease. American College of Physicians,
239. Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to aspirin in patients Philadelphia, 2008.
with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 260. Goldhaber SZ, Manson JE, Stampfer MJ, et al: Low-dose aspirin and subsequent
494–502, 2001. peripheral arterial surgery in the Physicians’ Health Study. Lancet 340:143–145, 1992.
240. Mehta SR: Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and 261. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspi-
PCI-CURE. J Invasive Cardiol 15 Suppl B:17B–20B, 2003. rin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339, 1996.
241. Hongo RH, Ley J, Dick SE, Yee RR: The effect of clopidogrel in combination with aspirin 262. Belch J, MacCuish A, Campbell I, et al: The prevention of progression of arterial dis-
when given before coronary artery bypass grafting. J Am Coll Cardiol 40:231–237, 2002. ease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of
242. Antoniucci D, Migliorini A, Parodi G, et al: Abciximab-supported infarct artery stent aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial
implantation for acute myocardial infarction and long-term survival: A prospective, disease. BMJ 337:a1840, 2008.
multicenter, randomized trial comparing infarct artery stenting plus abciximab with 263. Mohler E 3rd, Giri J: Management of peripheral arterial disease patients: Comparing
stenting alone. Circulation 109:1704–1706, 2004. the ACC/AHA and TASC-II guidelines. Curr Med Res Opin 24:2509–2522, 2008.
243. Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptor antagonists: A compara- 264. Gardner AW, Poehlman ET: Exercise rehabilitation programs for the treatment of clau-
tive review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs dication pain. A meta-analysis. JAMA 274:975–980, 1995.
3:423–436, 2003. 265. Murphy TP, Cutlip DE, Regensteiner JG, et al: Supervised exercise versus primary stent-
244. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a ing for claudication resulting from aortoiliac peripheral artery disease: Six-month out-
meta-analysis based on individual patients’ data. Lancet 359:294–302, 2002. comes from the claudication: Exercise versus endoluminal revascularization (CLEVER)
245. Lincoff AM, Kleiman NS, Kereiakes DJ, et al: Long-term efficacy of bivalirudin and study. Circulation 125:130–139, 2012.
provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa 266. Reilly MP, Mohler ER 3rd: Cilostazol: Treatment of intermittent claudication. Ann
blockade during percutaneous coronary revascularization: REPLACE-2 randomized Pharmacother 35:48–56, 2001.
trial. JAMA 292:696–703, 2004. 267. Wilhite DB, Comerota AJ, Schmieder FA, et al: Managing PAD with multiple platelet
246. Linkins LA, Dans AL, Moores LK, et al: Treatment and prevention of heparin-induced inhibitors: The effect of combination therapy on bleeding time. J Vasc Surg 38:710–713,
thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 2003.
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 268. Bogousslavsky J, Kaste M, Skyhoj OT, et al: Risk factors and stroke prevention. Euro-
Chest 141:e495S–530S, 2012. pean Stroke Initiative (EUSI). Cerebrovasc Dis 10 Suppl 3:12–21, 2000.
247. Fraker TD Jr, Fihn SD; Chronic Stable Angina Writing Committee, et al: 2007 chronic 269. Mohler ER 3rd, Delanty N, Rader DJ, Raps EC: Statins and cerebrovascular disease:
angina focused update of the ACC/AHA 2002 guidelines for the management of Plaque attack to prevent brain attack. Vasc Med 4:269–272, 1999.
patients with chronic stable angina: A report of the American College of Cardiology/ 270. Mohler ER 3rd: Carotid stenting for atherothrombosis. Heart 93:1147–1151, 2007.
American Heart Association Task Force on Practice Guidelines Writing Group to 271. Rerkasem K, Rothwell PM: Carotid endarterectomy for symptomatic carotid stenosis.
develop the focused update of the 2002 guidelines for the management of patients with Cochrane Database Syst Rev (4):CD001081, 2011.
chronic stable angina. J Am Coll Cardiol 50:2264–2274, 2007. 272. Halliday A, Harrison M, Hayter E, et al: 10-year stroke prevention after successful
248. Kaiser GC, Davis KB, Fisher LD, et al: Survival following coronary artery bypass graft- carotid endarterectomy for asymptomatic stenosis (ACST-1): A multicentre ran-
ing in patients with severe angina pectoris (CASS). An observational study. J Thorac domised trial. Lancet 376:1074–1084, 2010.
Cardiovasc Surg 89:513–524, 1985. 273. American College of Cardiology Foundation; American Society of Interventional &
249. Shaw LJ, Berman DS, Maron DJ, et al: Optimal medical therapy with or without per- Therapeutic Neuroradiology; Society for Cardiovascular Angiography and Interven-
cutaneous coronary intervention to reduce ischemic burden: Results from the Clinical tions, et al: ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) on carotid stenting: A report of the American College of Cardiology Foundation Task
trial nuclear substudy. Circulation 117:1283–1291, 2008. Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN
250. Mintz GS, Kimura T, Nobuyoshi M, Leon MB: Intravascular ultrasound assessment Clinical Expert Consensus Document Committee on Carotid Stenting). J Am Coll
of the relation between early and late changes in arterial area and neointimal hyper- Cardiol 49:126–170, 2007.
plasia after percutaneous transluminal coronary angioplasty and directional coronary 274. Diener HC, Cunha L, Forbes C, et al: European Stroke Prevention Study. 2. Dipyrida-
atherectomy. Am J Cardiol 83:1518–1523, 1999. mole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1–13,
251. Wilensky RL, Tanguay JF, Ito S, et al: Heparin Infusion Prior to Stenting (HIPS) trial: 1996.
Final results of a prospective, randomized, controlled trial evaluating the effects of local 275. Sacco RL, Diener HC, Yusuf S, et al: Aspirin and extended-release dipyridamole versus
vascular delivery on intimal hyperplasia. Am Heart J 139:1061–1070, 2000. clopidogrel for recurrent stroke. N Engl J Med 359:1238–1251, 2008.
252. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-elut- 276. Chowdhury R, Stevens S, Gorman D, et al: Association between fish consumption, long
ing stent with a standard stent for coronary revascularization. N Engl J Med 346: chain omega 3 fatty acids, and risk of cerebrovascular disease: Systematic review and
1773–1780, 2002. meta-analysis. BMJ 345:e6698.
253. Simonton CA, Brodie B, Cheek B, et al: Comparative clinical outcomes of paclitaxel- 277. Scolari F, Ravani P, Gaggi R, et al: The challenge of diagnosing atheroembolic renal
and sirolimus-eluting stents: Results from a large prospective multicenter registry— disease: Clinical features and prognostic factors. Circulation 116:298–304, 2012, 2007.
STENT Group. J Am Coll Cardiol 50:1214–1222, 2007. 278. Voetsch B, Afshar-Kharghan V, Loscalzo J, Schafer AI: Less common thrombotic and
254. Mohler ER 3rd: Peripheral arterial disease: Identification and implications. Arch Intern embolic disorders, in Thrombosis and Hemorrhage, edited by Loscalzo J and Schafer AI,
Med 163:2306–2314, 2003. pp 707–762. Lippincott Williams & Wilkins, Philadelphia, 2003.
255. Rooke TW, Hirsch AT, Misra S, et al: 2011 ACCF/AHA Focused update of the guide- 279. Quinones A, Saric M: The cholesterol emboli syndrome in atherosclerosis. Curr Athero-
line for the management of patients with peripheral artery disease (updating the 2005 scler Rep 15:315, 2013.
guideline): A report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 58:2020–2045,
2011.

Kaushansky_chapter 134_p2281-2302.indd 2302 17/09/15 3:50 pm